In alignment with our findings, sunitinib was active against acute myeloid leukemias (AML) possessing activating PDGFR, FLT-3, and c-kit mutations through inhibiting mTOR and reducing Mcl-1 levels (Ikezoe et al., 2006; Teng et al., 2013). The gene discussed is PDGFRB; the disease is acute myeloid leukemia.